A Multi-Center, Phase II Clinical Trial of PadexolTM (Paclitaxel) and Cisplatin for Patients Suffering with Advanced Gastric Cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: We conducted a multi-center, phase II trial to evaluate the efficacy and safety of using Padexol (a paclitaxel formulation) combined with cisplatin for thepatients suffering with advanced gastric adenocarcinoma. Materials and Methods: 39 patients (median age: 60 years; males: 90%) who were diagnosed with advanced gastric cancer were enrolled from 5 hospitals. Padexol175 mg/m2 was administered as a 3-hr infusion, and this was followed by cisplatin 75 mg/m2 as an intravenous infusion on day 1, once every 3 weeks. Results: Out of these 39 patients, 34 patients were assessable for treatment efficacy and 39 patients were assessable for the toxicity. Objective responses occurred in 13 patients (33%); 1 patient (3%) had a complete response and 12 patients (31%) had partial responses. 6 patients (15%) achieved a stable disease state. The median duration of response was 7.1 months, and the median time to progression and the overall survival were 4.8 months and 6.7 months, respectively. The major treatment-related adverse events were hematologic toxicity, including WHO grade 3 or 4 neutropenia in 13 patients (33%). However, febrile neutropenia occurred in only 1 patient and the non-hematologic toxicity was usually mild. Conclusion: The combination of Padexol and cisplatin was found to be active and it seems to be a relatively well-tolerated regimen for the treatment of advancedgastric cancer.
Abstract
Purpose: We conducted a multi-center, phase II trial to evaluate the efficacy and safety of using Padexol (a paclitaxel formulation) combined with cisplatin for the patients suffering with advanced gastric adenocarcinoma. Materials and Methods: 39 patients (median age: 60 years; males: 90%) who were diagnosed with advanced gastric cancer were enrolled from 5 hospitals. Padexol 175 mg/m2 was administered as a 3-hr infusion, and this was followed by cisplatin 75 mg/m2 as an intravenous infusion on day 1, once every 3 weeks. Results: Out of these 39 patients, 34 patients were assessable for treatment efficacy and 39 patients were assessable for the toxicity. Objective responses occurred in 13 patients (33%); 1 patient (3%) had a complete response and 12 patients (31%) had partial responses. 6 patients (15%) achieved a stable disease state. The median duration of response was 7.1 months, and the median time to progression and the overall survival were 4.8 months and 6.7 months, respectively. The major treatment-related adverse events were hematologic toxicity, including WHO grade 3 or 4 neutropenia in 13 patients (33%). However, febrile neutropenia occurred in only 1 patient and the non-hematologic toxicity was usually mild. Conclusion: The combination of Padexol and cisplatin was found to be active and it seems to be a relatively well-tolerated regimen for the treatment of advanced gastric cancer.
참고문헌 (21)
- "KCCR-affiliated Hospitals. 2002 Annual Report of the Korea Central Cancer Registry: based on registered data from 139 hospitals", 36, pp.103~14 (2004)
- "Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer", 8, pp.163~8 (1997)
- "Modified therapy with 5-fluorouracil and methotrexate in advanced gastric cancer", pp.37~41 (1993)
- "Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer.", 71, pp.587~91 (1995)
- "Taxol:a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms", 111, pp.273~9 (1989)
- "Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer", 85, pp.384~8 (1993)
- "Phase II trial of taxol an active drug in the treatment of metastatic breast cancer", pp.1797~805 (1991)
- "Phase II study of taxol in patients with advanced gastric carcinoma", 4, pp.269~74 (1998)
- "An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer", 21, pp.416~9 (1998)
- "A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinicacid and cisplatin in patients with advanced gastric cancer", 83, pp.458~62 (2000)
- "Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions", 12, pp.1133~7 (2001)
- "Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer", 14, pp.197~204 (2003)
- "Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer", 26, pp.37~41 (2003)
- "late phase II clinical trial of Genexol and cisplatin for patients with advanced gastric cancer", 12, pp.1059~64 (2004)
- "Designs for group sequential phase II clinical trials", 43, pp.865~74 (1987)
- "Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group", 18, pp.2648~57 (2000)
- "Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer", 15, pp.261~7 (1997)
- "Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293.", 13, pp.87~93 (1996)
- "CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study.", 94, pp.641~6 (2002)
- "Phase II study of oxaliplatin,fluorouracil,and folinic acid in locally advanced or metastatic gastric cancer patients", 20, pp.4543~8 (2002)
- "Phase II trial with S-1 in chemotherapynaive patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG).", 39, pp.1264~70 (2003)